These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38723388)

  • 1. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
    Holden H; Venkatesh S; Budrow C; Nezaria S; Coyle M; Centner A; Lipari N; McManus G; Bishop C
    Physiol Behav; 2024 Jul; 281():114563. PubMed ID: 38723388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
    Fang C; Yin J; Xu Z; Wang Y; Xu H; Zhou H; Gao C
    Cell Biochem Biophys; 2011 Jan; 59(1):49-56. PubMed ID: 20714825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
    Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Bishop C
    Behav Brain Res; 2014 Aug; 270():75-85. PubMed ID: 24837745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
    Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
    Barnum CJ; Bhide N; Lindenbach D; Surrena MA; Goldenberg AA; Tignor S; Klioueva A; Walters H; Bishop C
    Pharmacol Biochem Behav; 2012 Jan; 100(3):607-15. PubMed ID: 21978941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Winkler C; Kirik D; Björklund A; Cenci MA
    Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.
    Westin JE; Janssen ML; Sager TN; Temel Y
    Behav Brain Res; 2012 Jan; 226(2):519-28. PubMed ID: 22008381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
    Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
    Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
    Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Thornton E; Hassall MM; Corrigan F; Vink R
    Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
    Lipari N; Centner A; Glinski J; Cohen S; Manfredsson FP; Bishop C
    Neurobiol Dis; 2023 Jan; 176():105965. PubMed ID: 36526089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
    Chambers NE; Coyle M; Sergio J; Lanza K; Saito C; Topping B; Clark SD; Bishop C
    Eur J Neurosci; 2021 Apr; 53(8):2835-2847. PubMed ID: 33426708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
    Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
    Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
    Eskow Jaunarajs KL; George JA; Bishop C
    Neuroscience; 2012 Aug; 218():243-56. PubMed ID: 22659568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
    Marin C; Bonastre M; Fuentes M; Mullol J
    Pharmacol Biochem Behav; 2020 Oct; 197():173013. PubMed ID: 32758524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.